Prophylactic HIV Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Prophylactic HIV Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The global prophylactic HIV drug market is expected to register a CAGR of 4.1% during the forecast period.

The novel COVID-19 breakdown had augmented the need to evaluate the antiretroviral drugs to treat COVID-19 infections. The drugs such as lopinavir and ritonavir, which are used in combination to treat HIV, are repurposed to treat COVID-19 infections. Currently, several countries had evaluated the potential of these antiretroviral drugs for treating coronavirus infection. For instance, in August 2020, as per the World Health Organisation, Seventy-three countries have warned that they are at risk of stock-outs of antiretroviral (ARV) medicines as a result of the COVID-19 pandemic, according to a new WHO survey conducted ahead of the International AIDS Society’s biannual conference. Twenty-four countries reported having either a critically low stock of ARVs or disruptions in the supply of these life-saving medicines. The survey follows a modeling exercise convened by WHO and UNAIDS in May which forecasted that a six-month disruption in access to ARVs could lead to a doubling in AIDS-related deaths in sub-Saharan Africa in 2020 alone. In 2019, an estimated 8.3 million people were benefiting from ARVs in the 24 countries now experiencing supply shortages. This represents about one third (33%) of all people taking HIV treatment globally. While there is no cure for HIV, ARVs can control the virus and prevent onward sexual transmission to other people. Manufacturers of HIV drugs have also increased research capabilities and are also increasing the manufacturing capabilities of these drugs as they are extensively used for the symptomatic treatment of COVID-19. Prophylactic HIV drugs are used for the treatment of the human immunodeficiency virus (HIV).

The government announced stay-at-home orders due to the COVID-19 pandemic that caused disruption and restricted HIV testing and diagnosis, which led to a steep slowdown in referral and treatment for HIV and AIDS. However, from the start of 2021, the increasing prevalence of HIV among people and their inability to be treated due to staying at home will create a large patient pool and lead to the development of new treatment methods to prevent HIV infection. This will lead to the growth of the market. A large number of non-profit organizations and pharmaceutical and biotechnology companies are investing in HIV clinical research industry for its treatment therapies. For instance, in April 2021, non-profit organizations: IAVI and Scripps Research announced that they had completed a phase I clinical trial for a novel vaccine against HIV. In addition, Excision has announced that the FDA has approved its Investigational New Drug (IND) as a treatment to cure chronic HIV, which is called EBT-101.

The prevalence of HIV infection is rapidly increasing worldwide. The factors responsible for the growing prevalence rate include the widespread use of contaminated needles or syringes, unprotected sex, and, majorly, the lack of awareness about the mode of transmission. For instance, according to data published by the World Health Organization in April 2022, around 1.1 million Americans have HIV. About 15 percent of people ages 13 and older with HIV don’t know they have it. An estimated 39,782 Americans were newly diagnosed with HIV in 2016. In that same year, 18,160 individuals living with HIV developed stage 3 HIV or AIDS. The disease has mostly affected developing and underdeveloped countries on a larger scale due to the lack of adequate prevention measures and treatment facilities. The future growth of this market largely depends upon the treatment needs and unmet therapeutics present in Asian and African countries.

Several companies, such as Gilead Sciences Inc. and Cipla Inc., have also adopted patient education programs to reduce the adverse consequences of the infection. Moreover, several prophylactic HIV drugs for the treatment of HIV infection are currently in the pipeline. For instance, in April 2021, GS-9131 from Gilead Sciences is currently under Phase II, and it is being developed for the treatment of HIV with nucleoside reverse transcriptase inhibitors (NRTI) mechanism of action. However, lower penetration in an underdeveloped market and side effects associated with this drug, such as vomiting, nausea, tiredness, and diarrhea, may restrain the growth of the market.

Key Market TrendsOral Drug Forms are Expected to Dominate the Dosage Form Segment of the Market Studied

The oral drug segment is expected to dominate the global prophylactic HIV drug market, over the forecast period. This can be attributed to new product development and the presence of a strong pipeline coupled with rising product approvals. For instance, in September 2019, Merck received the United States and Food and Drug Administration to expand the use of Pifeltro and Delstrigo to include the treatment for virologically suppressed HIV adults. Also, in December 2021, the Food and Drug Administration approved a new drug in the fight against AIDS. It's the first injectable medication for HIV prevention. Cabotegravir is the first injectable form of HIV pre-exposure prophylaxis, a treatment also known as PrEP. Up until now, PrEP was available only in an oral form in which pills had to be taken every day. In clinical trials, cabotegravir proved to be 69% more effective than oral PrEP in preventing HIV among men who have sex with men. And it was 90% more effective than conventional PrEP among heterosexual women. The oral route also has several pharmacokinetic advantages such as a higher rate of bioavailability, rapid drug delivery, and high efficacy. All these advantages are expected to propel segment growth.

The oral route is the most patient compliance route, and therefore, it is most widely adopted by patients. Also, the development of promising new drugs and potential clinical pipeline candidates are some of the major factors expected to drive segment growth. The future growth of the market is anticipated to fuel by the launch of various potential pipeline candidates such as fostemsavir and PRO 140 and the launch of generic versions of various branded drugs such as tenofovir disoproxil fumarate tablets.

North America Represents the Largest Market in the Forecast Period

North America is one of the strongest regions and is also an important revenue contributor to the global HIV prophylactic drugs market. Heightened awareness of disease remittance therapies among patients, the presence of a technologically advanced healthcare framework, and supportive reimbursement policies are stimulating the growth of the region. As per the Department of Health & Human Services, In 2020, 30,635 people received an HIV diagnosis in the United States and dependent areas. According to the HIV Surveillance Report 2021 by the Government of Canada, in 2020, over 2,132 HIV diagnoses were reported in Canada 5.6 per 100,000 population. The age group 30 to 39 years had the highest HIV diagnosis rate at 12.7 per 100,000 population. Moreover, easy access to quality healthcare and a strong clinical pipeline is projected to promote revenue growth in North America. In July 2019, Merck, a US-based company, reported positive topline results for its HIV drug candidate MK-8591 from its pipeline.

In addition, there is an increasing incidence of the United States and Canadian government approval, which is one of the major reasons propelling the growth. For instance, in January 2020, Merck received United States Food and Drug Administration (FDA) approval for two new HIV-1 medicines: Delstrigo and Pifeltro, for commercialization of drugs in Canada and the United States. Hence, owing to all the aforementioned factors, the North American region is anticipated to grow at high growth rates.

Competitive Landscape

Manufacturers offering branded drugs dominate the global prophylactic HIV drugs market. Companies are building novel chemical entities and innovative molecules to consolidate their foothold. Some of the prominent market participants are AbbVie, APOTEX INC., Auro Pharma Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche AG (Genentech Inc.), Johnson & Johnson Health Care Systems Inc., Gilead Sciences Inc., Merck & Co. Inc., Upjohn (Mylan NV), Pfizer Inc., Teva Pharmaceutical Industries Ltd. and GlaxoSmithKline plc (ViiV Healthcare Group of Companies).

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.